Business
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass., May 07, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2026, along with recent product highlights and corporate updates.
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/eb4822879de76ff2b470f58687a146e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xLc_VCvBLgvQ4tSkHjlHnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0OA--/https://media.zenfs.com/en/business-wire.com/eb4822879de76ff2b470f58687a146e8","width":480,"height":224},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/b8Q1OJ82q2BRwAcO5Djymg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI5OQ--/https://media.zenfs.com/en/business-wire.com/eb4822879de76ff2b470f58687a146e8","width":480,"height":224}},"lazy":false},{"type":"text","content":"– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART","length":219,"tagName":"p"},{"type":"text","content":"– Zocilurtatug pelitecan (zoci) delivered standout data at AACR 2026, with a 62.5% confirmed intracranial ORR in SCLC patients with brain metastases, and clinically meaningful activity (38.2% confirmed ORR) across epNECs; registrational DLLEVATE trial ongoing with enrollment expected to complete in the first half of 2027","length":322,"tagName":"p"},{"type":"text","content":"– Collaborations with Amgen and Boehringer Ingelheim to evaluate zoci in combination with tarlatamab in SCLC and obrixtamig in SCLC and other NECs, positioning zoci as a potential backbone therapy","length":196,"tagName":"p"},{"type":"text","content":"– ZL-1503 (IL-13/IL-31Rα) demonstrated rapid, durable dual-pathway activity in preclinical data presented at IMMUNOLOGY2026, supporting less frequent dosing and broad potential across atopic diseases, including asthma; Phase 1/1b study underway with initial data expected in 2026","length":279,"tagName":"p"},{"type":"text","content":"– KarXT launch preparations are underway and TIVDAK remains under regulatory review; positive Phase 3 readouts for povetacicept in IgAN and elegrobart in TED providing additional growth opportunities for our regional business","length":225,"tagName":"p"},{"type":"text","content":"Conference call and webcast today, May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT)","length":79,"tagName":"p","attribs":{}},{"typ...